BACKAdult Mood Formula
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 23 February 2025]
We are inviting expressions of interest (EoI) for commercializing “Adult Mood Formula” technology. The innovation is developed by Professor NG Siew Chien, Professor of Department of Medicine & Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 25/MED/1482).
The Technology
Emerging evidence highlights the significant role of gut microbiota and the gut-brain axis. This invention discloses a synbiotic composition that is beneficial for mood disturbances.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
Adult Mood Formula
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 23 February 2025]
We are inviting expressions of interest (EoI) for commercializing “Adult Mood Formula” technology. The innovation is developed by Professor NG Siew Chien, Professor of Department of Medicine & Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 25/MED/1482).
The Technology
Emerging evidence highlights the significant role of gut microbiota and the gut-brain axis. This invention discloses a synbiotic composition that is beneficial for mood disturbances.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
N/A
Ms. Erika YUEN
Office of Research and Knowledge Transfer Services
Professor NG Siew Chien
N/A